Shanghai Modern Pharmaceutical Co., Ltd. Obtains Registration Certificate for Pentobarbital Injection

Recently, Shanghai Modern Pharmaceutical's wholly-owned subsidiary, Guoyao Industrial, received the "Drug Registration Certificate" for the injection of Butyroethoxy Ethoxy Quinolinium Chloride from the National Medical Products Administration, with a specification of 1ml:1mg. This drug is a selective anticholinergic drug used for pre-anesthetic medication, etc. Data from Minet Online shows that the sales revenue in public medical institutions nationwide is expected to increase year by year from 2022 to 2024. Currently, several other companies have also obtained the drug registration certificate and passed or been deemed to have passed consistency assessment. Guoyao Industrial has invested approximately 3.62 million yuan in research and development. Obtaining this certificate will enrich the company's product portfolio and enhance its competitiveness. However, the sales of the drug may be affected by various factors and thus, there is uncertainty, but it is not expected to have a major impact on the current performance of the company.